Idenix Pharmaceuticals, Inc. Announces Appointment of Susan Koppy as Senior Vice President, Business and Corporate Development
January 23 2006 - 7:30AM
PR Newswire (US)
CAMBRIDGE, Mass., Jan. 23 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (NASDAQ:IDIX) today announced the appointment
of Susan Koppy to the position of Senior Vice President, Business
and Corporate Development. Ms. Koppy has more than 20 years of
experience in marketing and business development in the
pharmaceutical industry. She has participated in the negotiation of
more than 10 major agreements with a multi-billion dollar aggregate
commercial value. At Idenix, Ms. Koppy will be responsible for
directing the company's strategic development, including licensing
agreements, joint ventures, strategic alliances and acquisitions.
Ms. Koppy was appointed subsequent to the resignation of James Egan
who left the company to pursue other interests. "We are pleased to
welcome Susan Koppy to the Idenix senior management team. Susan's
extensive experience and knowledge, focused on the licensing and
acquisition of technology and products, and her expertise in
building and fostering key relationships within the industry, will
contribute significantly to ensuring that Idenix maintains a robust
product candidate pipeline," said Jean-Pierre Sommadossi, Ph.D.,
chairman and chief executive officer of Idenix. "We thank Jamie
Egan for his contributions to Idenix, which have been instrumental
in assessing and securing key strategic collaborations for the
company." Prior to joining Idenix, Ms. Koppy served as the Vice
President of Strategy and Business Development at Applied
Biosystems, Inc., with responsibility for evaluation and pursuit of
licensing and acquisition opportunities. At ABI, Ms. Koppy also
created a company-wide strategic planning and business development
process. Before joining ABI, Ms. Koppy served as the Director of
Business Development for Novartis Pharmaceuticals Corporation where
she was responsible for global business development opportunities
in Infectious Diseases and was a key contributor to the formation
of the strategic alliance between Idenix and Novartis. Prior to her
work with the Novartis infectious disease franchise, Ms. Koppy
served as the Head of Commercial and Business Intelligence for
Novartis Pharma AG where she established and directed a commercial
and business intelligence group for pharmaceutical marketing. She
holds a bachelor's degree in genetics and cell biology from the
University of Minnesota as well as an undergraduate certificate in
science and engineering. About Idenix Idenix Pharmaceuticals, Inc.
is a biopharmaceutical company engaged in the discovery and
development of drugs for the treatment of human viral and other
infectious diseases. Idenix's current focus is on the treatment of
infections caused by hepatitis B virus, hepatitis C virus and human
immunodeficiency virus (HIV). Idenix's headquarters are located in
Cambridge, Massachusetts and it has drug discovery and development
operations in Montpellier, France and drug discovery operations in
Cagliari, Italy. For further information about Idenix, please refer
to http://www.idenix.com/. Forward-looking Statements This press
release contains "forward-looking statements" within the meaning of
The Private Securities Litigation Reform Act of 1995. Such
forward-looking statements can be identified by the use of
forward-looking terminology or by express or implied discussions
regarding the potential therapeutic benefits and successful
development of valopicitabine, or regarding any potential future
revenues from valopicitabine. Such forward-looking statements are
subject to numerous factors, risks and uncertainties that may cause
actual events or results to differ materially from the company's
current expectations. There can be no guarantee that valopicitabine
will be successfully developed or approved for sale in any market,
or that it will reach any particular level of revenue. In
particular, management's expectations regarding valopicitabine
could be affected by risks and uncertainties relating to the
results of clinical trials and other studies with respect to
valopicitabine, including further analysis of existing clinical
data, additional data from the ongoing phase IIb clinical trials
and data from any subsequent phase III clinical trials; the timing,
acceptance and approval, if any, of regulatory filings submitted to
the FDA or other regulatory bodies around the world, the company's
dependence on its collaboration with Novartis Pharma AG; the
company's ability to obtain additional funding required to conduct
its research, development and commercialization activities; the
ability of the company to attract and retain qualified personnel;
competition in general; and the company's ability to obtain,
maintain and enforce patent and other intellectual property
protection for valopicitabine. These and other risks which may
impact management's expectations regarding valopicitabine are
described in greater detail under the caption "Factors That May
Affect Future Results" in the company's quarterly report on Form
10-Q for the quarter ended September 30, 2005 and filed with the
Securities and Exchange Commission and other filings that the
company makes with the Securities and Exchange Commission. All
forward-looking statements reflect the company's expectations only
as of the date of this release and should not be relied upon as
reflecting the company's views, expectations or beliefs at any date
subsequent to the date of this release. Idenix anticipates that
subsequent events and developments may cause these views,
expectations and beliefs to change. However, while Idenix may elect
to update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. Idenix
Pharmaceuticals' Contacts Media: Teri Dahlman, 617-995-9905
Investors: Amy Sullivan, 617-995-9838 First Call Analyst: FCMN
Contact: DATASOURCE: Idenix Pharmaceuticals, Inc. CONTACT: Teri
Dahlman, +1-617-995-9905, or Amy Sullivan, +1-617-995-9838, both of
Idenix Pharmaceuticals, Inc. Web site: http://www.idenix.com/
Copyright
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024